Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Acquired platelet dysfunction following mithramycin therapy.

D J Ahr, S J Scialla, D B Kimbali

    Cancer
    |February 1, 1978
    PubMed
    Summary
    This summary is machine-generated.

    Mithramycin treatment for testicular tumors can cause bleeding issues, even without low platelets. This study found mithramycin impairs platelet function, leading to prolonged bleeding times and mucocutaneous bleeding.

    Related Experiment Videos

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Functional recovery in cancer rehabilitation.

    Archives of physical medicine and rehabilitation·2000
    Same author

    Case 27-1993: cerebral vasculitis.

    The New England journal of medicine·1994
    Same author

    A study of infusional cisplatin and infusional fluorouracil for locally advanced or metastatic non-small-cell lung cancer: a Mid-Atlantic Oncology Program study.

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology·1991
    Same author

    A heparin-like anticoagulant as part of global abnormalities of plasma glycosaminoglycans in a patient with transitional cell carcinoma.

    The Journal of laboratory and clinical medicine·1991
    Same author

    Jonathan Wainwright--pioneer in cancer control.

    Pennsylvania medicine·1987
    Same author

    Heparin monitoring by activated partial thromboplastin time. Comparison of ex vivo measurement and in vitro standardization.

    American journal of clinical pathology·1985

    Area of Science:

    • Oncology
    • Hematology
    • Pharmacology

    Background:

    • Mithramycin is used to treat testicular tumors.
    • Hemorrhagic diathesis (bleeding tendency) has been observed in patients receiving mithramycin.
    • This bleeding complication can occur without thrombocytopenia (low platelet count).